• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ETHICON INC. STRATAFIX SYMMETRIC PDS; SUTURE, SURGICAL, ABSORBABLE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ETHICON INC. STRATAFIX SYMMETRIC PDS; SUTURE, SURGICAL, ABSORBABLE Back to Search Results
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Wound Dehiscence (1154); Abscess (1690); Cellulitis (1768); Granuloma (1876); Unspecified Infection (1930); Post Operative Wound Infection (2446); No Code Available (3191)
Event Type  Injury  
Manufacturer Narrative
(b)(4).(b)(4).This report is related to data research, therefore no product will be returned for analysis and the batch history records cannot be reviewed as the lot number has not been provided.The single complaint was reported with multiple events.There are no additional details regarding the additional events.If further details are received at a later date a supplemental medwatch will be sent.If information is obtained that was not available for the initial report, a follow-up report will be filed as appropriate.
 
Event Description
It was reported via clinical evaluation report (cer) from a related research activity database (ddra) for patients undergoing an unknown procedure on an unknown date and suture was used.N = 579 patients (30-day follow-up) and the reported complication experienced by the following with corresponding intervention: 16 patients had complication after the index procedure on 30-day follow-up with the use of the device not present on admission were defined with the diagnosis code, surgical site infection; 3 patients had complication after the index procedure on 30-day follow-up with the use of the device not present on admission were defined with the diagnosis code, surgical site infection; 1 patient had complication after the index procedure on 30-day follow-up with the use of the device not present on admission were defined with the diagnosis code, surgical site infection; 1 patient had complication after the index procedure on 30-day follow-up with the use of the device not present on admission were defined with the diagnosis code, surgical site infection; 2 patients had complication after the index procedure on 30-day follow-up with the use of the device not present on admission were defined with the diagnosis code, wound dehiscence; 2 patients had complication after the index procedure on 30-day follow-up with the use of the device not present on admission were defined with the diagnosis code, wound dehiscence; 2 patients had complication after the index procedure on 30-day follow-up with the use of the device not present on admission were defined with the diagnosis code, other wound complications; 2 patients had complication after the index procedure on 30-day follow-up with the use of the device not present on admission were defined with the diagnosis code, other wound complications; 1 patient had complication after the index procedure on 30-day follow-up with the use of the device not present on admission were defined with the diagnosis code, cellulitis/abscess.No additional information was provided.
 
Manufacturer Narrative
(b)(4).Date sent to fda: 04/30/2021.This is a combination product, and the event has been reviewed for both the suture and the triclosan.This report is being submitted pursuant to the provisions of 21 cfr, part 803, part 4 subpart b.This report may be based on information which has not been investigated or verified prior to the required reporting date.This report does not reflect a conclusion by ethicon, or its employees that the report constitutes an admission that the product, ethicon, or its employees caused or contributed to the potential event described in this report.If information is obtained that was not available for the initial report, a follow-up report will be filed as appropriate.Trade name - irgacare®.Active ingredient(s) ¿ triclosan.Dosage form ¿ suture/solid/parenteral.Strength ¿ = 2360 g/m (b)(4).Date sent to fda: 04/30/2021.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
STRATAFIX SYMMETRIC PDS
Type of Device
SUTURE, SURGICAL, ABSORBABLE
Manufacturer (Section D)
ETHICON INC.
1000 route 202
raritan NJ 08876
MDR Report Key10792719
MDR Text Key214798186
Report Number2210968-2020-08692
Device Sequence Number1
Product Code NEW
Combination Product (y/n)N
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type other
Type of Report Initial,Followup,Followup
Report Date 04/19/2021
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received11/05/2020
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Was Device Available for Evaluation? No
Date Manufacturer Received04/19/2021
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
-
-